These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 26630452)
1. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452 [TBL] [Abstract][Full Text] [Related]
2. Current pharmacotherapy for testicular germ cell cancer. Alsdorf W; Seidel C; Bokemeyer C; Oing C Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243 [TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors. Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945 [TBL] [Abstract][Full Text] [Related]
6. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors. Bokemeyer C Oncology; 1998; 55(3):177-88. PubMed ID: 9560052 [TBL] [Abstract][Full Text] [Related]
7. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. Oing C; Lorch A Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M; J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040 [TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649 [TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340 [TBL] [Abstract][Full Text] [Related]
11. Third-line chemotherapy and novel agents for metastatic germ cell tumors. Veenstra CM; Vaughn DJ Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610 [TBL] [Abstract][Full Text] [Related]
12. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Cohn-Cedermark G; Stahl O; Tandstad T; Andrology; 2015 Jan; 3(1):102-10. PubMed ID: 25270123 [TBL] [Abstract][Full Text] [Related]
13. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Cullen M Ann Oncol; 2012 Sep; 23 Suppl 10():x342-8. PubMed ID: 22987989 [TBL] [Abstract][Full Text] [Related]
14. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature. Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942 [TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042 [TBL] [Abstract][Full Text] [Related]
16. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059 [TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. Lorch A; Rick O; Wündisch T; Hartmann JT; Bokemeyer C; Beyer J J Urol; 2010 Jul; 184(1):168-73. PubMed ID: 20483152 [TBL] [Abstract][Full Text] [Related]
18. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937 [TBL] [Abstract][Full Text] [Related]
19. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. Kawai K; Akaza H Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501 [TBL] [Abstract][Full Text] [Related]
20. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]